A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder


The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).

Full Title of Study: “A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: October 2022

Detailed Description

This is a randomized, double-blind, placebo-controlled, 3-arm, parallel-group, multi-center study. Participants will attend a Screening Visit to confirm eligibility and then return to the clinic within 14 days to be randomized into the study. Randomized participants will receive a single dose of their allocated study intervention (225 mg BNC210, 675 mg BNC210 or placebo) and approximately 1 hour later participate in a speaking challenge. After 1 week, a safety follow-up assessment will be conducted by phone/video conference.


  • Drug: 225 mg BNC210
    • 225 mg BNC210
  • Drug: 675 mg BNC210
    • 675 mg BNC210
  • Drug: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Experimental: 225 mg BNC210
  • Experimental: 675 mg BNC210
  • Placebo Comparator: Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Subjective Units of Distress Scale (SUDS) – speaking challenge performance phase
    • Time Frame: 1 Day

Secondary Measures

  • Subjective Units of Distress Scale (SUDS) – speaking challenge anticipation phase
    • Time Frame: 1 Day
  • State-Trait Anxiety Inventory (State component; STAI-State)
    • Time Frame: 1 Day
  • Self-Statements During Public Speaking Scale (Negative Self-Statements subscale; SSPS-N)
    • Time Frame: 1 Day

Participating in This Clinical Trial

Inclusion Criteria

  • Participant has a current diagnosis of Social Anxiety Disorder (SAD) as defined in DSM-5 and confirmed by Structured Clinical Interview for DSM-5 Disorders – Clinical Trials version (SCID-5-CT). – Liebowitz Social Anxiety Scale (LSAS) total score of ≥70 – Suitable contraception use in line with protocol requirements – Ability to swallow tablets Exclusion Criteria:

  • History of schizophrenia, bipolar disorder, or psychotic disorders, or has a current clinically predominant diagnosis of any other Axis I disorder, other than SAD – Hamilton Rating Scale for Depression (HAM-D) score of ≥18 – Moderate or severe alcohol-use disorder, or any other substance-use disorder (any severity) in the past 12 months – Use of psychotropic medications within 30 days of screening. Daily use of benzodiazepines within 90 days of screening. – Previous participation in a study that involved a speaking challenge. – Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bionomics Limited
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • BNC210 Clinical Studies Bionomics Limited, +61 8 8150 7400, bnc210clinicalstudies@bionomics.com.au

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.